The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Current Status of Platinum-Based Antitumor Drugs
Wong, E., & Giandomenico, C. M. (1999) · Chemical Reviews · doi:10.1021/cr980420v · Cited by 1,800
Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug
(1999) · Wiley eBooks · doi:10.1002/9783906390420 · Cited by 1,296
New metal complexes as potential therapeutics
Zhang, C. X., & Lippard, S. J. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00081-4 · Cited by 946
Non-Platinum Chemotherapeutic Metallopharmaceuticals
Clarke, M. J., Zhu, F., & Frasca, D. R. (1999) · Chemical Reviews · doi:10.1021/cr9804238 · Cited by 908
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
Rademaker-Lakhai, J. M., van den Bongard, D., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0746 · Cited by 833
Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes
Morris, R. E., Aird, R. E., del Socorro Murdoch, P., Chen, H., Cummings, J., Hughes, N. D., Parsons, S., Parkin, A., Boyd, G., Jodrell, D. I., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010051m · Cited by 787
Metals and DNA: Molecular Left-Handed Complements
Barton, J. K. (1986) · Science · doi:10.1126/science.3016894 · Cited by 752
Metal complexes in cancer chemotherapy
Keppler, B. K. (1993) · Medical Entomology and Zoology · Cited by 688
Ruthenium metallopharmaceuticals
Clarke, M. J. (2003) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00312-0 · Cited by 687
Cisplatin: From DNA damage to cancer chemotherapy
Cohen, S. M., & Lippard, S. J. (2001) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(01)67026-0 · Cited by 615
Aird, R. E., Cummings, J., Ritchie, A. A., Muir, M., Morris, R. E., Chen, H., Sadler, P. J., & Jodrell, D. I. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600290 · Cited by 582
Ruthenium Antimetastatic Agents
Alessio, E., Mestroni, G., Bergamo, A., & Sava, G. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043387421 · Cited by 479
New Cisplatin Analogues in Development: A Review
Weiss, R. B., & Christian, M. C. (1993) · Drugs · doi:10.2165/00003495-199346030-00003 · Cited by 404
Modifications of DNA by platinum complexes
Brabec, V., & Kasparkova, J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.006 · Cited by 373
Self-citationClinical Perspectives on Platinum Resistance
Giaccone, G. (2000) · Drugs · doi:10.2165/00003495-200059004-00002 · Cited by 364
Recognition of cisplatin adducts by cellular proteins
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00142-7 · Cited by 349
Platinum‐based anticancer agents: Innovative design strategies and biological perspectives
Ho, Y., Au‐Yeung, S. C. F., & To, K. K. W. (2003) · Medicinal Research Reviews · doi:10.1002/med.10038 · Cited by 329
Wang, F., Chen, H., Parsons, S., Oswald, I. D. H., Davidson, J. E., & Sadler, P. J. (2003) · Chemistry – A European Journal · doi:10.1002/chem.200304724 · Cited by 254
Correlation between Cytotoxicity and DNA Binding of Polypyridyl Ruthenium Complexes
Novakova, O., Kasparkova, J., Vrana, O., van Vliet, P. M., Reedijk, J., & Brabec, V. (1995) · Biochemistry · doi:10.1021/bi00038a034 · Cited by 246
Self-citationDNA Modifications by antitumor platinum and ruthenium compounds: Their recognition and repair
(2002) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(02)71040-4 · Cited by 230
Pongratz, M., Schluga, P., Jakupec, M. A., Arion, V. B., Hartinger, C. G., Allmaier, G., & Keppler, B. K. (2004) · Journal of Analytical Atomic Spectrometry · doi:10.1039/b309160k · Cited by 206
The binding properties of two antitumor ruthenium(III) complexes to apotransferrin.
Kratz, F., Hartmann, M., Keppler, B., & Messori, L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41984-3 · Cited by 204
Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells
Kapitza, S., Pongratz, M., Jakupec, M. A., Heffeter, P., Berger, W., Lackinger, L., Keppler, B. K., & Marian, B. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0617-0 · Cited by 200
Metal Antitumor Compounds: The Mechanism of Action of Platinum Complexes
Johnson, N. P., Butour, J.-L., Villani, G., Wimmer, F. L., Defais, M., Pierson, V., & Brabec, V. (1989) · Progress in Clinical Biochemistry and Medicine · doi:10.1007/978-3-642-74760-1_1 · Cited by 158
Self-citationNováková, O., Kašpárková, J., Bursová, V., Hofr, C., Vojtíšková, M., Chen, H., Sadler, P. J., & Brabec, V. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.11.008 · Cited by 136
Self-citationCisplatin Resistance and Transcription Factors
Torigoe, T., Izumi, H., Ishiguchi, H., Yoshida, Y., Tanabe, M., Yoshida, T., Igarashi, T., Niina, I., Wakasugi, T., Imaizumi, T., et al. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011053352587 · Cited by 133
Current status of the development of trans-platinum antitumor drugs
Perez, J. M. T., Fuertes, M. A., Alonso‐Moreno, C., & Navarro‐Ranninger, C. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00053-6 · Cited by 125
Kapitza, S. B., Jakupec, M. A., Uhl, M., Keppler, B. K., & Marian, B. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.002 · Cited by 119
Ruthenium-based compounds and tumour growth control (review).
Sava, G., & Bergamo, A. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.2.353 · Cited by 118
Molecular mechanisms of platinum resistance: still searching for the Achilles? heel
Wernyj, R. P., & Morin, P. J. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.08.002 · Cited by 114
Farrell, N. (1996) · PubMed · Cited by 102
Neyhart, G. A., Cheng, C., & Thorp, H. H. (1995) · Journal of the American Chemical Society · doi:10.1021/ja00110a001 · Cited by 77
Covalent Binding of Aquaruthenium Complexes to DNA
Grover, N., Welch, T. W., Fairley, T. A., Cory, M., & Thorp, H. H. (1994) · Inorganic Chemistry · doi:10.1021/ic00094a018 · Cited by 70
Bergamo, A., Zorzet, S., Gava, B., Sorc, A., Alessio, E., Iengo, E., & Sava, G. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200009000-00012 · Cited by 60
Antitumor Active Trans-Platinum Compounds
Natile, G., & Coluccia, M. (2004) · CRC Press eBooks · doi:10.1201/b12414-7 · Cited by 46
Anticancer Activity of Cisplatin and Related Complexes
Gelasco, A. K., & Lippard, S. J. (1999) · Springer eBooks · doi:10.1007/978-3-662-03815-4_1 · Cited by 37
Bergamo, A., Stocco, G., Gava, B., Cocchietto, M., Alessio, E., Serli, B., Iengo, E., & Sava, G. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.047803 · Cited by 27
Cited by
Recent developments in ruthenium anticancer drugs
Levina, A., Mitra, A., & Lay, P. A. (2009) · Metallomics · doi:10.1039/b904071d · Cited by 592
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
Approaching tumour therapy beyond platinum drugs
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.09.030 · Cited by 514
Ruthenium complexes as antimicrobial agents
Li, F., Collins, J. G., & Keene, F. R. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00343h · Cited by 467
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
Bergamo, A., & Sava, G. (2011) · Dalton Transactions · doi:10.1039/c0dt01816c · Cited by 440
Metadata
- Authors
- Brabec, V., & Nováková, O.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2006-06
- Volume
- 9
- Issue
- 3
- Pages
- 111-122
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2005603971
- Cited by
- 384
- References
- 41
- FWCI
- 9.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.